ReviewAmerican family physician2009
Cardiomyopathy: an overview.
Review in American family physician, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Hypertrophic Cardiomyopathy in Saudi Arabia: A Systematic Review of the Epidemiological, Clinical, and Imaging Features.Current cardiology reviews · 2023Pooled it
- Meta-analysis of cardiomyopathy-associated variants in troponin genes identifies loci and intragenic hot spots that are associated with worse clinical outcomes.Journal of molecular and cellular cardiology · 2020Pooled it
- Native TJournal of magnetic resonance imaging : JMRI · 2018Pooled it
- Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.The Cochrane database of systematic reviews · 2012Pooled it
- Emerging Technologies in Cardiovascular Disease Modeling: Bridging Basic Science and Clinical Translation.Cells · 2026Review
- Transfer RNA-derived small RNAs in cardiovascular diseases: Progress and perspectives.Non-coding RNA research · 2026Review
- The Heart of the Thymus: A Rare Tale of Nonischemic Cardiomyopathy in the Absence of Myasthenia Gravis.Clinical case reports · 2026Article
- Organelle homeostasis disruption: A driving force in the progression of cardiomyopathy (Review).Experimental and therapeutic medicine · 2026Review
- CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases.Molecular therapy. Nucleic acids · 2026Review
- In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin-Induced Cardiomyopathy.Chemistry & biodiversity · 2026Article
- Systemic barriers and opportunities for equity in early implementation of genetic testing and counseling for cardiomyopathies in Tanzania.Communications medicine · 2025Review
- Recent Advances of Pluripotent Stem Cell-Derived Cardiomyocytes for Regenerative Medicine.Metabolites · 2025Review
- Missense variants in the myosin binding domains ofbioRxiv : the preprint server for biology · 2025Article
- Chronic hepatitis C and the risk for atherosclerotic and cardiomyopathic heart disease.World journal of hepatology · 2025Review
- Nexilin mutations, a cause of chronic heart failure: A state-of-the-art review starting from a clinical case.World journal of cardiology · 2025Review
- Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- GPR40-full agonist AM1638 alleviates palmitate-induced oxidative damage in H9c2 cells via an AMPK-dependent pathway.BMB reports · 2025Article
- Identification of novel genetic variants associated with feline cardiomyopathy using targeted next-generation sequencing.Scientific reports · 2025Article
- Metabolic perturbations in cardiomyopathies: implications for early diagnosis and targeted interventions.Frontiers in cardiovascular medicine · 2025Review
- HCM-Echo-VAR-Ensemble: Deep Ensemble Fusion to Detect Hypertrophic Cardiomyopathy in Echocardiograms.IEEE open journal of engineering in medicine and biology · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- SummaryForPatientsIn
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cardiomyopathy is an anatomic and pathologic diagnosis associated with muscle or electrical dysfunction of the heart. Cardiomyopathies represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Cardiomyopathies may be primary (i.e., genetic, mixed, or acquired) or secondary (e.g., infiltrative, toxic, inflammatory). Major types include dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. Although cardiomyopathy is asymptomatic in the early stages, symptoms are the same as those characteristically seen in any type of heart failure and may include shortness of breath, fatigue, cough, orthopnea, paroxysmal nocturnal dyspnea, and edema. Diagnostic studies include B-type natriuretic peptide levels, baseline serum chemistries, electrocardiography, and echocardiography. Treatment is targeted at relieving the symptoms of heart failure and reducing rates of heart failure-related hospitalization and mortality. Treatment options include pharmacotherapy, implantable cardioverter-defibrillators, cardiac resynchronization therapy, and heart transplantation. Recommended lifestyle changes include restricting alcohol consumption, losing weight, exercising, quitting smoking, and eating a low-sodium diet.
Indexed as
Identifiers
20141097PMC2999879W108613969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.